Scanvio raises USD 3.4M to advance AI-guided ultrasound for endometriosis diagnosis
15.07.2025
Swiss startup Scanvio Medical closes oversubscribed Seed Round to accelerate the development of its diagnostic tool for a widely underdiagnosed condition.
 |
 |
Endometriosis affects roughly one in ten women globally and is often misdiagnosed or overlooked for years. The Medtech company Scanvio Medical has secured USD 3.4 million in seed funding to further develop its AI-based ultrasound assistant for earlier and more accurate diagnosis of endometriosis. The oversubscribed round attracted support from a broad network of angel investors and family offices in Switzerland and Germany, including StartAngels, superangels, Stöckli Medical, Venture Kick, Kickfund, SICTIC, and S2S Ventures.
A Venture Leaders alum and Venture Kick winner, Scanvio aims to close the diagnostic gap by providing clinicians with a real-time AI assistant that integrates with standard pelvic ultrasound procedures, reducing reliance on highly specialized expertise.
The company is already collaborating with hospitals in Switzerland, Austria, France, and Egypt and is preparing for CE and FDA regulatory clearance.
"Venture Kick's fast-paced approach and expert feedback created invaluable momentum exactly when we needed it most. The funding of the final “kick” was instrumental in getting our AI solution into clinical practice for the first time, ultimately enabling us to demonstrate real-world impact and successfully close the seed round,” highlighted Stefan Tuchschmid, CEO and Founder of Scanvio.
A Venture Leaders alum and Venture Kick winner, Scanvio aims to close the diagnostic gap by providing clinicians with a real-time AI assistant that integrates with standard pelvic ultrasound procedures, reducing reliance on highly specialized expertise.
The company is already collaborating with hospitals in Switzerland, Austria, France, and Egypt and is preparing for CE and FDA regulatory clearance.
"Venture Kick's fast-paced approach and expert feedback created invaluable momentum exactly when we needed it most. The funding of the final “kick” was instrumental in getting our AI solution into clinical practice for the first time, ultimately enabling us to demonstrate real-world impact and successfully close the seed round,” highlighted Stefan Tuchschmid, CEO and Founder of Scanvio.